Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast Cancer
Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.
Recent Videos
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Oncotype DX Used for Patients With Breast Cancer to Guide Therapy
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer
Mitigating Toxicities With Oral SERDs and Other Breast Cancer Therapies
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
Breast Cancer Study Shows Minimal Score Variation After Radiation Boost
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
Shortened Radiation Trial Advances Breast Cancer Treatment
Understanding the Significance of ESR1 Mutations in Breast Cancer
Related Content
